Core Viewpoint - Crystal Technology Holdings (02228) has seen a stock price increase of over 4%, currently at HKD 11.92, with a trading volume of HKD 22.59 billion, following its inclusion in the FTSE China Small Cap Index, which enhances capital attention and liquidity premium [1][1][1] Company Performance - Crystal Technology Holdings has achieved its first profitable quarter, reporting a revenue of RMB 517 million for the first half of the year, representing a year-on-year growth of 403.8% [1][1][1] - The adjusted net profit for the company is RMB 141.6 million, marking its first half-year profitability [1][1][1] - The company has secured a significant contract worth nearly USD 6 billion, validating its AI pharmaceutical commercialization capabilities [1][1][1] Strategic Developments - The partnership with DoveTree has contributed positively to the company's revenue growth [1][1][1] - Progress has been made in embodied intelligence (e.g., agile spoons) and Multi-Agent systems [1][1][1]
港股异动 | 晶泰控股(02228)涨超4% 近日获纳入富时中国小盘股 AI制药商业化能力获得验证